As Celgene becomes BMS, its I&I lead lands CEO job at Takeda spinoff

As Celgene gradually phases into parent company Bristol-Myers Squibb, this is leaving little room at the inn for some of the top execs.

Terrie Curran, president of global inflammation and immunology at Celgene, is one such leader looking for pastures new amid the acquisition: Now, she has found her home at Phathom Pharmaceuticals. (Well, she will as soon as the BMS deal officially closes.)